Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Jessica K. Ortwine"'
Autor:
Helen Ding, Norman S. Mang, Jordan Loomis, Jessica K. Ortwine, Wenjing Wei, Ellen J. O’Connell, Nainesh J. Shah, Bonnie C. Prokesch
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 8 (2024)
ABSTRACT The 2019 Infectious Diseases Society of America guideline for the management of community-acquired pneumonia (CAP) emphasizes the need for clinician to understand local epidemiological data to guide selection of appropriate treatment. Curren
Externí odkaz:
https://doaj.org/article/7829a0eb4bc0485d97cbebbb1c0f080d
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 1 (2023)
ABSTRACT Dalbavancin is a second-generation lipoglycopeptide antibiotic with activity against Gram-positive organisms. Dalbavancin is Food and Drug Administration (FDA)-approved for acute bacterial skin and soft tissue infections (ABSSTIs). There is
Externí odkaz:
https://doaj.org/article/5447fa8113144f419986f1801e89a1ec
Autor:
Khalid Eljaaly, Jessica K. Ortwine, Mohammed Shaikhomer, Thamer A. Almangour, Matteo Bassetti
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 24, Iss , Pp 424-428 (2021)
Objectives: This study was conducted to evaluate the efficacy and safety of eravacycline, a recently approved fluorocycline for treatment of complicated intra-abdominal infections (cIAIs). Methods: PubMed, EMBASE and three trial registries were searc
Externí odkaz:
https://doaj.org/article/e120a2a5b3cc40238bc013db2585358a
Autor:
Kevin Lin, Yorgo Zahlanie, Jessica K. Ortwine, Wenjing Wei, Norman S. Mang, Bonnie C. Prokesch
Publikováno v:
PLoS ONE, Vol 17, Iss 9 (2022)
Background The current Infectious Diseases Society of America guidelines for the treatment of acute uncomplicated pyelonephritis (AUP) advise caution when using oral beta-lactams due to concern for potentially inferior efficacy compared to fluoroquin
Externí odkaz:
https://doaj.org/article/19e2bda199af4fd0863d0f0e3317b666
Autor:
Sarah C. J. Jorgensen, Kyle P. Murray, Abdalhamid M. Lagnf, Sarah Melvin, Sahil Bhatia, Muhammad-Daniayl Shamim, Jordan R. Smith, Karrine D. Brade, Samuel P. Simon, Jerod Nagel, Karen S. Williams, Jessica K. Ortwine, Michael P. Veve, James Truong, David B. Huang, Susan L. Davis, Michael J. Rybak
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 1, Pp 89-106 (2020)
Abstract Background We sought to determine the real-world incidence of and risk factors for vancomycin-associated acute kidney injury (V-AKI) in hospitalized adults with acute bacterial skin and skin structure infections (ABSSSI). Methods Retrospecti
Externí odkaz:
https://doaj.org/article/b1972c958ffe464ba5f0ed226230571c
Autor:
Jessica K. Ortwine, Evan J. Zasowski, Jason M. Pogue, Claudia Hanni, Chris Giuliano, Anthony M. Casapao, Ryan Mynatt, Michael J. Rybak
Publikováno v:
Infectious Diseases and Therapy, Vol 8, Iss 4, Pp 627-640 (2019)
Abstract Introduction A one-time vancomycin loading dose of 25–30 mg/kg is recommended in the current iteration of the vancomycin consensus guidelines in order to more rapidly achieve target serum concentrations and hasten clinical improvement. How
Externí odkaz:
https://doaj.org/article/4335b6e9131d48c7b44743dfda0bea98
Publikováno v:
Journal of Infection and Public Health, Vol 11, Iss 5, Pp 727-731 (2018)
Background: Anti-staphylococcal penicillins have long been the first-line treatment option for methicillin-susceptible Staphylococcus aureus (MSSA) infections. Recent retrospective data comparing nafcillin and cefazolin report similar clinical effica
Externí odkaz:
https://doaj.org/article/94a6c47e22134182a077274e7bf00fe2
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 19, Iss 4 (2016)
Purpose: Gram-negative resistance continues to rise with treatment options becoming more limited. Ceftazidime/avibactam was recently approved in the United States and Europe, which combines an established third-generation cephalosporin with a new, un
Externí odkaz:
https://doaj.org/article/cacd307452fe4a1aa8132abdcdd6fd8d
Publikováno v:
Microbiology spectrum.
Dalbavancin is a second-generation lipoglycopeptide antibiotic with activity against Gram-positive organisms. Dalbavancin is Food and Drug Administration (FDA)-approved for acute bacterial skin and soft tissue infections (ABSSTIs). There is a lack of
Autor:
Karrine D. Brade, Abdalhamid M Lagnf, Sarah C J Jorgensen, Susan L. Davis, Michael P. Veve, Muhammad-Daniayl Shamim, Jerod Nagel, Michael J. Rybak, James Truong, David B. Huang, Jordan R. Smith, Karen S Williams, Samuel Simon, Sarah M Melvin, Kyle P. Murray, Jessica K Ortwine, Sahil Bhatia
Publikováno v:
Infectious Diseases and Therapy
Infectious Diseases and Therapy, Vol 9, Iss 1, Pp 89-106 (2020)
Infectious Diseases and Therapy, Vol 9, Iss 1, Pp 89-106 (2020)
BackgroundWe sought to determine the real-world incidence of and risk factors for vancomycin-associated acute kidney injury (V-AKI) in hospitalized adults with acute bacterial skin and skin structure infections (ABSSSI).MethodsRetrospective, observat